Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00023946
Status:
TERMINATED
Last Update Posted:
2014-05-14
First Post:
2001-09-13
Brief Title:
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
A Phase II Trial Of The Epothilone B Analog BMS-247550 NSC 710428D In Patients With Hepatobiliary Cancer
Status:
TERMINATED
Status Verified Date:
2012-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II trial to study the effectiveness of BMS-247550 in treating patients who have liver or gallbladder cancer Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
Detailed Description:
PRIMARY OBJECTIVES
I Determine the objective response rate of patients with hepatobiliary cancer treated with BMS-247550
II Determine the toxicity of this drug in these patients III Determine the duration of response median and overall survival and time to progression in patients treated with this drug
OUTLINE This is a multicenter study
Patients receive BMS-247550 IV over 3 hours on day 1 Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 6 weeks until disease progression
I Determine the objective response rate of patients with hepatobiliary cancer treated with BMS-247550
II Determine the toxicity of this drug in these patients III Determine the duration of response median and overall survival and time to progression in patients treated with this drug
OUTLINE This is a multicenter study
Patients receive BMS-247550 IV over 3 hours on day 1 Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity
Patients are followed every 6 weeks until disease progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| N01CM62201 | NIH | CTEP | httpsreporternihgovquickSearchN01CM62201 |
| NCI-2012-02407 | REGISTRY | None | None |
| CDR0000068878 | None | None | None |
| NCI-3656 | None | None | None |
| UCCRC-11045 | None | None | None |
| UC11045A | OTHER | None | None |
| 3656 | OTHER | None | None |
| P30CA014599 | NIH | None | None |